BioAtla, Inc. cash flow to debt ratio of -777.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioAtla, Inc.'s free cash flow has increased -32.99% from $-71.94M last year to $-48.20M, signaling increasing performance

BioAtla, Inc.'s debt to equity ratio is -0.16, signaling that the company spent its equity and risk bankruptcy.

BioAtla, Inc.'s debt to equity ratio is -0.16, signaling that the company spent its equity and risk bankruptcy.

BioAtla, Inc. has a net cash position, so leverage is healthy.

BioAtla, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BioAtla, Inc.'s profit margin has decreased (298.98%) in the last year from -634.33% to -2.53K%, signaling decreasing performance

BioAtla, Inc.'s short-term liabilities of $21.92M exceed its short-term assets of $8.01M, signaling financial risk

BioAtla, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioAtla, Inc.'s return on equity of 166.67%, is higher than 15.00%, indicating good performance

BioAtla, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioAtla, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

BioAtla, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BioAtla, Inc. has negative free cash flow, indicating cash burn

BioAtla, Inc.'s yearly earnings has increased -14.57% since last year from $-69.78M to $-59.61M, signaling increasing performance

BioAtla, Inc.'s yearly revenue has decreased 100.00% since last year from $11.00M to $0.00, signaling decreasing performance

ROIC 477.89% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

BioAtla, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

BioAtla, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

BioAtla, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioAtla, Inc. has insufficient data to evaluate this check.

BioAtla, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioAtla, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioAtla, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioAtla, Inc. has insufficient data to evaluate this check.

BioAtla, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioAtla, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

BioAtla, Inc. has a price-to-sales ratio of 2.61x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue